A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
BRIGNONE, Chrystelle, ESCUDIER, Bernard, GRYGAR, Caroline, MARCU, Manon, TRIEBEL, Frédéric
Published in Clinical cancer research (01.10.2009)
Published in Clinical cancer research (01.10.2009)
Get full text
Journal Article
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
Atkinson, Victoria, Khattak, Adnan, Haydon, Andrew, Eastgate, Melissa, Roy, Amitesh, Prithviraj, Prashanth, Mueller, Christian, Brignone, Chrystelle, Triebel, Frederic
Published in Journal for immunotherapy of cancer (01.11.2020)
Published in Journal for immunotherapy of cancer (01.11.2020)
Get full text
Journal Article
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
Brignone, Chrystelle, Gutierrez, Maya, Mefti, Fawzia, Brain, Etienne, Jarcau, Rosana, Cvitkovic, Frédérique, Bousetta, Nabil, Medioni, Jacques, Gligorov, Joseph, Grygar, Caroline, Marcu, Manon, Triebel, Frédéric
Published in Journal of translational medicine (23.07.2010)
Published in Journal of translational medicine (23.07.2010)
Get full text
Journal Article
MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis
Hemon, Patrice, Jean-Louis, Francette, Ramgolam, Kiran, Brignone, Chrystelle, Viguier, Manuelle, Bachelez, Hervé, Triebel, Frédéric, Charron, Dominique, Aoudjit, Fawzi, Al-Daccak, Reem, Michel, Laurence
Published in The Journal of immunology (1950) (01.05.2011)
Published in The Journal of immunology (1950) (01.05.2011)
Get full text
Journal Article
Immunophenotyping of Peripheral Blood Mononuclear Cells in Septic Shock Patients With High-Dimensional Flow Cytometry Analysis Reveals Two Subgroups With Differential Responses to Immunostimulant Drugs
Wang, Ya, Gloss, Brian, Tang, Benjamin, Dervish, Suat, Santner-Nanan, Brigitte, Whitehead, Christina, Masters, Kristy, Skarratt, Kristen, Teoh, Sally, Schibeci, Stephen, Fewings, Nicole, Brignone, Chrystelle, Triebel, Frederic, Booth, David, McLean, Anthony, Nalos, Marek
Published in Frontiers in immunology (22.03.2021)
Published in Frontiers in immunology (22.03.2021)
Get full text
Journal Article
Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300
Grossman, Steven R., Deato, Maria E., Brignone, Chrystelle, Chan, Ho Man, Kung, Andrew L., Tagami, Hideaki, Nakatani, Yoshihiro, Livingston, David M.
Published in Science (American Association for the Advancement of Science) (11.04.2003)
Published in Science (American Association for the Advancement of Science) (11.04.2003)
Get full text
Journal Article
595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab
Forster, Martin, Felip, Enriqueta, Majem, Margarita, Doger, Bernard, Clay, Tim, Carcereny, Enric, Bondarenko, Igor, Peguero, Julio, Dols, Manuel Cobo, Ursol, Grygorii, Kalinka, Ewa, Ledo, Gema Garcia, Martinez, Laia Vilà, Krebs, Matthew, Iams, Wade T, Mueller, Christian, Brignone, Chrystelle, Triebel, Frederic
Published in Journal for immunotherapy of cancer (01.11.2023)
Published in Journal for immunotherapy of cancer (01.11.2023)
Get full text
Journal Article
948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC
Wildiers, Hans, Dirix, Luc, Armstrong, Anne, Cuypere, Eveline De, Dalenc, Florence, Chan, Steven, Marme, Frederik, Schröder, Carolina Pia, Huober, Jens, Vuylsteke, Peter, Jacquin, Jean-Philippe, Brain, Etienne, Kümmel, Sherko, Pápai, Zsuzsanna, Mueller, Christian, Brignone, Chrystelle, Triebel, Frederic
Published in Journal for immunotherapy of cancer (01.11.2021)
Published in Journal for immunotherapy of cancer (01.11.2021)
Get full text
Journal Article
790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)
Krebs, Matthew, Majem, Margarita, Felip, Enriqueta, Forster, Martin, Doger, Bernard, Clay, Tim, Carcereny, Enric, Peguero, Julio, Horn, Leora, Bajaj, Pawan, Roxburgh, Patricia, Brignone, Chrystelle, Mueller, Christian, Triebel, Frederic
Published in Journal for immunotherapy of cancer (01.11.2020)
Published in Journal for immunotherapy of cancer (01.11.2020)
Get full text
Journal Article
A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway
BRIGNONE, Chrystelle, BRADLEY, Kathleen E, KISSELEV, Alexei F, GROSSMAN, Steven R
Published in Oncogene (20.05.2004)
Published in Oncogene (20.05.2004)
Get full text
Journal Article
Recruitment of the Actin-binding Protein HIP-55 to the Immunological Synapse Regulates T Cell Receptor Signaling and Endocytosis
Le Bras, Séverine, Foucault, Isabelle, Foussat, Arnaud, Brignone, Chrystelle, Acuto, Oreste, Deckert, Marcel
Published in The Journal of biological chemistry (09.04.2004)
Published in The Journal of biological chemistry (09.04.2004)
Get full text
Journal Article
A LAG-3-Specific Agonist Antibody for the Treatment of T Cell-Induced Autoimmune Diseases
Angin, Mathieu, Brignone, Chrystelle, Triebel, Frédéric
Published in The Journal of immunology (1950) (15.02.2020)
Published in The Journal of immunology (1950) (15.02.2020)
Get full text
Journal Article
Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma
Forster, Martin, Brana, Irene, Pousa, Antonio L, Doger, Bernard, Roxburgh, Patricia, Bajaj, Pawan, Peguero, Julio, Krebs, Matthew, Carcereny, Enric, Patel, Grisma, Mueller, Christian, Brignone, Chrystelle, Triebel, Frederic
Published in Clinical cancer research (03.09.2024)
Published in Clinical cancer research (03.09.2024)
Get full text
Journal Article
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
Wildiers, Hans, Armstrong, Anne, Cuypere, Eveline, Dalenc, Florence, Dirix, Luc, Chan, Steve, Marme, Frederik, Schröder, Carolina P, Huober, Jens, Duhoux, Francois P, Vuylsteke, Peter, Jager, Agnes, Brain, Etienne, Kuemmel, Sherko, Pápai, Zsuzsanna, Menke-van der Houven van Oordt, Catharina Willemien, Perjesi, Luca, Mueller, Christian, Brignone, Chrystelle, Triebel, Frederic
Published in Clinical cancer research (01.02.2024)
Published in Clinical cancer research (01.02.2024)
Get full text
Journal Article
Abstract PD14-08: Primary efficacy results from AIPAC: A double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients
Wildiers, Hans, Armstrong, Anne, Cuypere, Eveline, Dalenc, Florence, Dirix, Luc, Chan, Steve, Marme, Frederik, Schröder, Carolina Pia, Huober, Jens, Wagemans, Jill, Vuylsteke, Peter, Jacquin, Jean-Philippe, Brain, Etienne, Kümmel, Sherko, Pápai, Zsuzsanna, Perjesi, Luca, Mueller, Christian, Brignone, Chrystelle, Triebel, Frederic
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Published in Cancer research (Chicago, Ill.) (15.02.2021)
Get full text
Journal Article
LAG-3 ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
BRIGNONE CHRYSTELLE, SABATOS PEYTON CATHERINE ANNE, CHANG HWAI WEN, BLATTLER WALTER A, MATARAZA JENNIFER MARIE, FREY GERHARD JOHANN, TRIEBEL FREDERIC
Year of Publication 12.07.2024
Get full text
Year of Publication 12.07.2024
Patent